StreetInsider.com News Articles

Cosmos Health projects $15M in Q4 U.S. revenue as subscriptions rise 42%

Mon, 19 Oct 2026 09:31:45 -0400

Cosmos Health Inc. (NASDAQ: COSM) said it expects approximately $15 million in U.S. revenue for the fourth quarter ending December 31, 2026, with gross profit of approximately $10.5 million, according to a company statement issued October 19, 2026.

The company said active U.S. subscriptions reached 8,940 as of October 19, up 42% from 6,287 reported five days earlier on October 14. Monthly subscription value at standard renewal pricing rose 44% over the same period to approximately $1.3 million.

Subscription revenue is expected to account for approximately $11.5 million, or more than three-quarters, of the projected quarterly total. That figure includes approximately $8.2

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in

Mon, 19 Oct 2026 09:30:00 -0400

CHICAGO, IL / ACCESS Newswire / October 19, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, based on its current growth trajectory, it expects U.S. revenue of approximately $15 million for the fourth quarter of 2026, with gross profit of approximately $10.5 million. Subscriptions are expected to generate more than three-quarters of fourth quarter U.S. revenue, and momentum toward this outlook continues to build: as of October 19, 2026, active U.S. subscriptions reached 8,940, up 42% from

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in

Mon, 19 Oct 2026 09:30:00 -0400

Form SCHEDULE 13G/A Cosmos Health Inc. Filed by: Bovopoulos Andreas

Fri, 16 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261016/27198303.html

Cosmos Health reports 6,287 U.S. subscriptions since mid-September launch

Wed, 14 Oct 2026 09:31:30 -0400

Cosmos Health Inc. (NASDAQ: COSM) reported that its U.S. online stores have reached 6,287 active subscriptions as of October 14, 2026, with substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026.

According to a company statement, its subscription management platform has tracked 10,881 U.S. online checkout orders to date, of which 60.5% included a subscription. The company said the subscription rate has recently climbed above 75% of checkout orders.

The 6,287 active subscriptions comprise 12,408 subscription lines and 14,793 product units, averaging approximately 2.4 units per subscription. At standard renewal pricing, the aggregate

Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription

Wed, 14 Oct 2026 09:30:00 -0400

CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has reached 6,287 active subscriptions in its U.S. online stores, substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026. Overall, 60.5% of the U.S. online checkout orders tracked by the Company's subscription management platform have included a subscription, with adoption accelerating in recent days.

CHICAGO, IL / ACCESS Newswire / October 14, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has reached 6,287 active subscriptions in its U.S. online stores, substantially all of them added since mid-September 2026, following the launch of its subscription model in mid-July 2026. Overall, 60.5% of the U.S. online checkout orders tracked by the Company's subscription management platform have included a subscription, with adoption accelerating in recent days.

CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than $92,000 in a single day on October 11, 2026. Sales over the past 30 days totaled $902,000, while average daily sales over the past 10 days exceeded $60,000, double the 30-day average.

United States Direct-to-Consumer Sales

The figures cover sales through

Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days

Tue, 13 Oct 2026 09:30:00 -0400

CHICAGO, IL / ACCESS Newswire / October 13, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its United States direct-to-consumer sales reached a record of more than $92,000 in a single day on October 11, 2026. Sales over the past 30 days totaled $902,000, while average daily sales over the past 10 days exceeded $60,000, double the 30-day average.

United States Direct-to-Consumer Sales

The figures cover sales through

Form 8-K Cosmos Health Inc. For: Oct 07

Fri, 09 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261009/27172158.html

Cosmos Health posts $54.3M in nine-month revenue, up 19%

Wed, 07 Oct 2026 09:45:17 -0400

Cosmos Health Inc. (NASDAQ: COSM) reported preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026, a 19% increase from $45.6 million in the same period of 2025, according to a company statement.

Third-quarter preliminary revenue came in at approximately $17.4 million, compared with $17.1 million in the third quarter of 2025 and $12.4 million in the third quarter of 2024. The nine-month figure compares with full-year 2024 revenue of $54.4 million and full-year 2025 revenue of $65.3 million.

The company attributed the revenue increase to growth across its core segments. Its contract manufacturing subsidiary, Cana Laboratories, reported

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

Wed, 07 Oct 2026 09:30:00 -0400

CHICAGO, IL / ACCESS Newswire / October 7, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026 - a Company record and an increase of 19%, or $8.7 million, over the $45.6 million reported for the same period of 2025. Preliminary revenue for the third quarter was approximately $17.4 million, the highest third quarter in the Company's history. The Company also reaffirmed its expectation that

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

Wed, 07 Oct 2026 09:30:00 -0400

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

Thu, 01 Oct 2026 15:58:00 -0400

CHICAGO, IL / ACCESS Newswire / October 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an overview of its brand portfolio and the global markets it addresses. The portfolio comprises more than 15 proprietary brands and product lines and 10 branded generics across five product categories, sold in more than 40 countries through pharmacies, hospitals, retail chains and e-commerce. It is manufactured at GMP-certified facilities in Europe and the United States and supported by the Company's services in contract

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

Thu, 01 Oct 2026 15:58:00 -0400

CosmoFarm hits $60M annualized revenue run-rate in Q2 2026

Tue, 29 Sep 2026 09:31:38 -0400

Cosmos Health Inc. (NASDAQ: COSM) reported that its Greek pharmaceutical distribution subsidiary, CosmoFarm S.A., recorded revenue of more than $15 million in the second quarter of 2026, representing an annualized run-rate of over $60 million.

According to a company statement, that figure is approximately 4.3 times the roughly $14 million in annual sales CosmoFarm generated in fiscal 2017, the last full year before Cosmos Health acquired the business. The compound annual growth rate over the period is approximately 18%, though the company notes that figures are expressed in U.S. dollars and reflect euro/dollar exchange rate movements.

CosmoFarm operates a 29,100-square-foot distribution center

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Reven

Tue, 29 Sep 2026 09:30:00 -0400

CHICAGO, IL / ACCESS Newswire / September 29, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its wholly owned pharmaceutical distribution subsidiary, CosmoFarm S.A. ("CosmoFarm"), which delivered record revenue of over $15 million in the second quarter of 2026, representing an annualized revenue run-rate of over $60 million.

A Leading Pharmaceutical Distribution Platform

CosmoFarm is a fully licensed pharmaceutical wholesaler

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Reven

Tue, 29 Sep 2026 09:30:00 -0400

A Leading Pharmaceutical Distribution Platform

CosmoFarm is a fully licensed pharmaceutical wholesaler

Cosmos Health CMO pipeline tops 32.7M units with $20M implied revenue

Mon, 28 Sep 2026 08:02:16 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced that the contract manufacturing pipeline of its subsidiary Cana Laboratories S.A. has surpassed $20 million in implied revenue and $18 million in implied gross profit across agreements covering more than 32.7 million units.

The figures represent aggregate amounts over the life of the underlying agreements, which average approximately four years in duration, with some extending up to ten years. On an annualized basis, the pipeline equates to approximately $5 million in implied annual revenue and $4.5 million in implied annual gross profit. The company stated that implied gross margins exceed 90%. These are management estimates

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

Mon, 28 Sep 2026 08:00:00 -0400

CHICAGO, IL / ACCESS Newswire / September 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that the contract manufacturing ("CMO") pipeline of its wholly owned subsidiary, Cana Laboratories S.A. ("Cana"), has surpassed $20 million in implied revenue over the life of the underlying agreements, representing over $18 million in implied gross profit at gross margins of over 90%, as the production pipeline reaches a record of more than 32.7 million units.

The CMO pipeline is spread

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

Mon, 28 Sep 2026 08:00:00 -0400

The CMO pipeline is spread

Cosmos Health unit signs 5.2M-unit deal with Target Pharma

Tue, 15 Sep 2026 10:31:36 -0400

Cosmos Health Inc. (NASDAQ: COSM) announced that its subsidiary Cana Laboratories S.A. has secured five-year contract manufacturing agreements with Target Pharma covering approximately 5.2 million units, according to a company press release.

The agreements cover two products: Mupirocin, a topical antibiotic, at approximately 900,000 units annually, and Tretin, an isotretinoin-based acne treatment, at approximately 140,000 units annually. Combined, the contracts total roughly 1.04 million units per year over five years.

The new agreements bring Cana's cumulative orderbook to more than 32.7 million units, a 31% increase since June 2026. The company states that 7.7 million units were added in September alone, including

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Tue, 15 Sep 2026 10:30:00 -0400

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today
Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma
Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026
Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows
Division targeted to generate over $10 million in recurring annual profit at full capacity

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

Tue, 15 Sep 2026 10:30:00 -0400

7.7 million contracted units added in under two weeks - Cana Laboratories' orderbook has grown from over 12 million units earlier this year to more than 32.7 million today
Secured orders for 1.04 million units annually - 5.2 million over five years - under new agreements with Target Pharma
Coverage extended to 11 therapeutic categories with the addition of cardiovascular and anti-infective, up from nine in June 2026
Agreements extending up to ten years provide long-term visibility on production volumes and associated cash flows
Division targeted to generate over $10 million in recurring annual profit at full capacity